An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice

The adenosine analogue galidesivir (BCX4430), a broad-spectrum RNA virus inhibitor, has entered a phase 1 clinical safety and pharmacokinetics study in healthy subjects and is under clinical development for treatment of Ebola and yellow fever virus infections. Moreover, galidesivir also inhibits the...

Full description

Saved in:
Bibliographic Details
Published in:J Virol
Main Authors: Eyer, Ludek, Nougairède, Antoine, Uhlířová, Marie, Driouich, Jean-Sélim, Zouharová, Darina, Valdés, James J., Haviernik, Jan, Gould, Ernest A., De Clercq, Erik, de Lamballerie, Xavier, Ruzek, Daniel
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2019
Subjects:
Vaccines and Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675905/
https://ncbi.nlm.nih.gov/pubmed/31142664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00367-19
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items